Business Insider

Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome

LEXINGTON, Mass., June 6, 2018 /PRNewswire/ -- Commercial-stage cancer biotech company, Partner Therapeutics, Inc. (PTx), announced the recent FDA approval of Leukine for the treatment of adult and ...
Business Insider

Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)

LEXINGTON, Mass., Feb. 18, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of ...
JSTOR Daily

Rapid Prediction of Hematologic Acute Radiation Syndrome in Radiation Injury Patients Using Peripheral Blood Cell Counts

Radiation Research, Vol. 188, No. 2 (August 2017), pp. 156-168 (13 pages) Rapid clinical triage of radiation injury patients is essential for determining appropriate diagnostic and therapeutic ...
Morningstar

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia and Lymphocyte Exhaustion Tivic Health® Systems, ...
Business Wire

Synedgen Receives Contract from BARDA to Develop MIIST305 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome

CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced a partnership valued at up to $119 million ...
GEN

Studies Suggest Stockpiles of Stem Cells from Fat Could Treat Acute Radiation Syndrome in Mass Populations

There are currently no effective, safe approaches that are suitable for treating acute radiation syndrome (ARS) in mass populations exposed to deadly levels of radiation in the event of a nuclear ...
JSTOR Daily

Citrulline as a Biomarker for Gastrointestinal-Acute Radiation Syndrome: Species Differences and Experimental Condition Effects

Animal models of hematopoietic and gastrointestinal acute radiation syndromes (ARS) have been characterized to develop medical countermeasures. Acute radiation-induced decrease of intestinal ...
KTLA

Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of ...

LEXINGTON, Mass., Sept. 9, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the European Commission has granted a marketing authorization in the European Union (EU) for ...
Business Wire

Synedgen Announces $2.2 Million JWMRP Award for MIIST305 For Use as a Prophylactic Radiation Medical Countermeasure

CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced that it has been awarded a $2.2 million ...